ADC Therapeutics Q1 Financial Results Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: seekingalpha
- Revenue Performance: ADC Therapeutics reported a Q1 non-GAAP EPS of -$0.13 with revenues of $20.85 million, reflecting a 9.5% year-over-year decline but exceeding expectations by $0.86 million, demonstrating resilience amid market fluctuations.
- Product Revenue Growth: The net product revenue for Q1 reached $20 million, up from $17.4 million in Q1 2025, primarily driven by normal variability in customer ordering patterns and price increases, indicating stability in product demand.
- Decline in License Revenue: License revenues and royalties fell to $0.8 million from $5.6 million in Q1 2025, primarily due to a milestone payment received in the prior year, highlighting the volatility in revenue sources.
- Cash Flow Status: As of March 31, 2026, cash and cash equivalents stood at $231 million, with an expected cash runway extending at least into 2028, ensuring operational stability for the company in the coming years.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.190
Low
5.00
Averages
7.33
High
10.00
Current: 1.190
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADC Therapeutics Completes Enrollment for ZYNLONTA Clinical Trial
- Trial Enrollment Completion: ADC Therapeutics announced the completion of enrollment for 100 patients with relapsed or refractory diffuse large B-cell lymphoma in the LOTIS-7 clinical trial, all receiving a 150 µg/kg dose of ZYNLONTA combined with glofitamab, highlighting the company's leadership in the antibody-drug conjugate field.
- Patient Demographics: The trial included 46% relapsed and 54% primary refractory patients, with a median age of 66 years, aligning with baseline characteristics seen in other bispecific combination studies, indicating broad applicability and clinical relevance of the research.
- Preliminary Efficacy Data: Among 49 efficacy-evaluable patients, the combination of ZYNLONTA and glofitamab demonstrated an 89.8% overall response rate and a 77.6% complete response rate, suggesting strong clinical potential for treating relapsed or refractory DLBCL and positioning it as a best-in-class option for 2L+ therapy.
- Future Data Release Plans: ADC Therapeutics plans to present full data from LOTIS-7 at a medical meeting by the end of 2026 and submit results for publication, further assessing regulatory and compendia pathways for the combination, reflecting the company's focus on future market opportunities.
See More
ADC Therapeutics Completes Enrollment for ZYNLONTA Clinical Trial
- Trial Enrollment Completion: ADC Therapeutics announced the completion of enrollment for the LOTIS-7 trial, with 100 patients with relapsed or refractory DLBCL receiving a 150 µg/kg dose of ZYNLONTA combined with glofitamab, underscoring the company's leadership in the ADC field.
- Safety and Efficacy Assessment: The primary endpoints focus on safety and tolerability, while secondary endpoints include overall response rate and duration of response, which are expected to provide critical data for future regulatory submissions, further solidifying the company's competitive edge in the market.
- Clinical Data Outlook: Previous reports indicated an 89.8% overall response rate and a 77.6% complete response rate among 49 efficacy-evaluable patients, suggesting that the ZYNLONTA combination may become the best-in-class option for second-line and beyond treatment of DLBCL.
- Future Development Plans: ADC Therapeutics plans to share comprehensive results from LOTIS-7 by the end of 2026 and assess potential regulatory pathways for the combination, demonstrating the company's confidence in new therapies and its ongoing innovation in cancer treatment.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
ADC Therapeutics Initiates Strategic Reorganization and Workforce Reduction
- Workforce Reduction: ADC Therapeutics announced a 17% workforce reduction to focus resources on advancing the ZYNLONTA franchise, which is expected to generate annual cost savings of approximately $10 million, although it will incur one-time pre-tax charges of about $3 million.
- Clinical Trial Progress: The company anticipates completing the Phase 3 LOTIS-5 and LOTIS-7 trials in 2026, and successful outcomes from these trials will enhance ZYNLONTA's market positioning in treating large B-cell lymphoma, thereby increasing its competitive edge.
- Regulatory Path Planning: ADC Therapeutics plans to hold a pre-sBLA meeting with the FDA in August 2026 to discuss the potential regulatory pathway for ZYNLONTA in combination with rituximab, with an sBLA submission expected in Q4 2026, which will further facilitate the product's market entry.
- Market Performance Volatility: Over the past year, ADC Therapeutics' stock price fluctuated between $0.78 and $4.98, closing at $1.07, down 6.96%, indicating market caution regarding the company's reorganization and clinical developments.
See More
ADC Therapeutics Cuts 17% Workforce to Focus on ZYNLONTA
- Workforce Reduction: ADC Therapeutics announced a 17% global workforce cut aimed at focusing on the ZYNLONTA franchise and its clinical and regulatory milestones, which is expected to generate annual cost savings of approximately $10 million.
- Clinical Trial Progress: The company anticipates completing the LOTIS-5 and LOTIS-7 trials in 2026, both evaluating the efficacy of its targeted cancer therapy ZYNLONTA, with the outcomes directly impacting future regulatory applications.
- Increased Financial Flexibility: Through this reorganization, ADC Therapeutics plans to recognize about $3 million in one-time pre-tax charges in Q2 2026, aiming to enhance financial flexibility to support upcoming regulatory milestones.
- Bearish Market Sentiment: Despite the restructuring efforts, retail sentiment on Stocktwits remains bearish towards ADCT, indicating market concerns about the company's future, with the stock down over 67% year-to-date.
See More
ADC Therapeutics Plans 17% Workforce Reduction to Enhance Financial Flexibility
- Workforce Reduction: ADC Therapeutics announced a global workforce reduction of approximately 17%, expected to generate annual savings of about $10 million, aimed at enhancing financial flexibility and supporting key value-driving initiatives for the ZYNLONTA® franchise.
- Clinical Milestones: The company is scheduled to meet with the FDA in August 2026 to discuss the potential regulatory path for ZYNLONTA in combination with rituximab for treating relapsed or refractory large B-cell lymphoma, with an sBLA submission anticipated in Q4 2026.
- Trial Progress: ADC is advancing the LOTIS-7 trial, evaluating the efficacy of ZYNLONTA in combination with glofitamab, with data expected by the end of 2026, which will support the company's further development in the lymphoma space.
- Financial Impact: While the company anticipates incurring approximately $3 million in one-time pre-tax charges for employee severance and related costs, it expects to maintain a sufficient cash runway into 2028, ensuring ongoing operations and research capabilities.
See More
ADC Therapeutics Completes Enrollment for ZYNLONTA Clinical Trial
- Trial Enrollment Completion: ADC Therapeutics announced the completion of enrollment for 100 patients with relapsed or refractory diffuse large B-cell lymphoma in the LOTIS-7 clinical trial, all receiving a 150 µg/kg dose of ZYNLONTA combined with glofitamab, highlighting the company's leadership in the antibody-drug conjugate field.
- Patient Demographics: The trial included 46% relapsed and 54% primary refractory patients, with a median age of 66 years, aligning with baseline characteristics seen in other bispecific combination studies, indicating broad applicability and clinical relevance of the research.
- Preliminary Efficacy Data: Among 49 efficacy-evaluable patients, the combination of ZYNLONTA and glofitamab demonstrated an 89.8% overall response rate and a 77.6% complete response rate, suggesting strong clinical potential for treating relapsed or refractory DLBCL and positioning it as a best-in-class option for 2L+ therapy.
- Future Data Release Plans: ADC Therapeutics plans to present full data from LOTIS-7 at a medical meeting by the end of 2026 and submit results for publication, further assessing regulatory and compendia pathways for the combination, reflecting the company's focus on future market opportunities.
See More
ADC Therapeutics Completes Enrollment for ZYNLONTA Clinical Trial
- Trial Enrollment Completion: ADC Therapeutics announced the completion of enrollment for the LOTIS-7 trial, with 100 patients with relapsed or refractory DLBCL receiving a 150 µg/kg dose of ZYNLONTA combined with glofitamab, underscoring the company's leadership in the ADC field.
- Safety and Efficacy Assessment: The primary endpoints focus on safety and tolerability, while secondary endpoints include overall response rate and duration of response, which are expected to provide critical data for future regulatory submissions, further solidifying the company's competitive edge in the market.
- Clinical Data Outlook: Previous reports indicated an 89.8% overall response rate and a 77.6% complete response rate among 49 efficacy-evaluable patients, suggesting that the ZYNLONTA combination may become the best-in-class option for second-line and beyond treatment of DLBCL.
- Future Development Plans: ADC Therapeutics plans to share comprehensive results from LOTIS-7 by the end of 2026 and assess potential regulatory pathways for the combination, demonstrating the company's confidence in new therapies and its ongoing innovation in cancer treatment.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
ADC Therapeutics Initiates Strategic Reorganization and Workforce Reduction
- Workforce Reduction: ADC Therapeutics announced a 17% workforce reduction to focus resources on advancing the ZYNLONTA franchise, which is expected to generate annual cost savings of approximately $10 million, although it will incur one-time pre-tax charges of about $3 million.
- Clinical Trial Progress: The company anticipates completing the Phase 3 LOTIS-5 and LOTIS-7 trials in 2026, and successful outcomes from these trials will enhance ZYNLONTA's market positioning in treating large B-cell lymphoma, thereby increasing its competitive edge.
- Regulatory Path Planning: ADC Therapeutics plans to hold a pre-sBLA meeting with the FDA in August 2026 to discuss the potential regulatory pathway for ZYNLONTA in combination with rituximab, with an sBLA submission expected in Q4 2026, which will further facilitate the product's market entry.
- Market Performance Volatility: Over the past year, ADC Therapeutics' stock price fluctuated between $0.78 and $4.98, closing at $1.07, down 6.96%, indicating market caution regarding the company's reorganization and clinical developments.
See More
ADC Therapeutics Cuts 17% Workforce to Focus on ZYNLONTA
- Workforce Reduction: ADC Therapeutics announced a 17% global workforce cut aimed at focusing on the ZYNLONTA franchise and its clinical and regulatory milestones, which is expected to generate annual cost savings of approximately $10 million.
- Clinical Trial Progress: The company anticipates completing the LOTIS-5 and LOTIS-7 trials in 2026, both evaluating the efficacy of its targeted cancer therapy ZYNLONTA, with the outcomes directly impacting future regulatory applications.
- Increased Financial Flexibility: Through this reorganization, ADC Therapeutics plans to recognize about $3 million in one-time pre-tax charges in Q2 2026, aiming to enhance financial flexibility to support upcoming regulatory milestones.
- Bearish Market Sentiment: Despite the restructuring efforts, retail sentiment on Stocktwits remains bearish towards ADCT, indicating market concerns about the company's future, with the stock down over 67% year-to-date.
See More
ADC Therapeutics Plans 17% Workforce Reduction to Enhance Financial Flexibility
- Workforce Reduction: ADC Therapeutics announced a global workforce reduction of approximately 17%, expected to generate annual savings of about $10 million, aimed at enhancing financial flexibility and supporting key value-driving initiatives for the ZYNLONTA® franchise.
- Clinical Milestones: The company is scheduled to meet with the FDA in August 2026 to discuss the potential regulatory path for ZYNLONTA in combination with rituximab for treating relapsed or refractory large B-cell lymphoma, with an sBLA submission anticipated in Q4 2026.
- Trial Progress: ADC is advancing the LOTIS-7 trial, evaluating the efficacy of ZYNLONTA in combination with glofitamab, with data expected by the end of 2026, which will support the company's further development in the lymphoma space.
- Financial Impact: While the company anticipates incurring approximately $3 million in one-time pre-tax charges for employee severance and related costs, it expects to maintain a sufficient cash runway into 2028, ensuring ongoing operations and research capabilities.
See More
